{
    "clinical_study": {
        "@rank": "105738", 
        "arm_group": [
            {
                "arm_group_label": "MEDI4736 Q2W", 
                "arm_group_type": "Experimental", 
                "description": "Evaluate MEDI4736 given every 2 weeks"
            }, 
            {
                "arm_group_label": "MEDI4736 Q3W", 
                "arm_group_type": "Experimental", 
                "description": "Evaluate MEDI4736 given every 3 weeks"
            }, 
            {
                "arm_group_label": "MEDI4736 Dose Expansion", 
                "arm_group_type": "Experimental", 
                "description": "At least 8 different types of solid tumors will be evaluated in the expansion phase"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, open-label, first-time-in-human study with a standard 3+3\n      dose-escalation phase in subjects with advanced solid tumors followed by an expansion phase\n      in patients with advanced solid tumors."
        }, 
        "brief_title": "A Phase 1 Study to Evaluate MEDI4736", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "A  dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets\n      programmed cell death-1 ligand 1 (PD-L1)) will evaluate the safety, tolerability, PK, IM,\n      and antitumor activity of MEDI4637 in adult patients with solid tumors."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Age 18 or older.  In the dose-escalation phase: histologically- or cytologically-\n        confirmed advanced solid tumor that is refractory to standard therapy and for which no\n        standard therapy exists.\n\n          -  In the dose-expansion phase: histologically- or cytologically- confirmed advanced\n             solid tumor where if an approved first-line therapy is available, subjects must have\n             failed, be intolerant to, be ineligible for, or have refused treatment.\n\n          -  Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.\n\n          -  Adequate organ and marrow function.\n\n          -  Subjects must have at least 1 measurable lesion.\n\n          -  Available archived tumor tissue sample.\n\n          -  Willingness to provide consent for biopsy samples (dose-expansion only)\n\n        Exclusion Criteria:\n\n          -  Any prior Grade \u2265 3 irAE while receiving immunotherapy\n\n          -  Prior exposure to any anti-PD-1 or anti-PD-L1 antibody\n\n          -  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer\n             treatment.\n\n          -  Active or prior documented autoimmune disease within the past 2 years\n\n          -  History of primary immunodeficiency\n\n          -  History of organ transplant that requires use of immunosuppressives\n\n          -  Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent\n             treatment\n\n          -  Other invasive malignancy within 5 years\n\n          -  Women who are pregnant or lactating\n\n          -  Uncontrolled intercurrent illness\n\n          -  Known history of tuberculosis\n\n          -  Known to be human immunodeficiency virus (HIV) positive\n\n          -  Known to be Hepatitis B or C positive"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693562", 
            "org_study_id": "CD-ON-MEDI4736-1108"
        }, 
        "intervention": {
            "arm_group_label": [
                "MEDI4736 Q2W", 
                "MEDI4736 Q3W", 
                "MEDI4736 Dose Expansion"
            ], 
            "description": "MEDI4736 will be administered by IV infusion every 14 or 21 days.", 
            "intervention_name": "MEDI4736", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Advanced solid tumors", 
            "Advanced Malignant Melanoma", 
            "Non-small Cell Lung Cancer", 
            "Advanced Cutaneous Melanoma", 
            "Uveal Melanoma", 
            "Hepatocellular Carcinoma", 
            "Squamous Cell Carcinomal of the Head and Neck", 
            "Gastroesophageal Cancer", 
            "Triple Negative Breast Cancer", 
            "Pancreatic Adenocarcinoma"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "France", 
                "Italy"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Roxanne Akhavain", 
            "phone": "301-398-0000"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "James Vasselli, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "MTD or OBD will be determined by the number of participants experiencing dose-limiting toxicities.\nSafety profile will be assessed through number of participants experiencing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, and physical examinations.", 
                "measure": "Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs).", 
                "safety_issue": "Yes", 
                "time_frame": "90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "Evaluate the objective response rate in subjects with non-squamous NSCLC who have received 2 or more prior lines of therapy and subjects with squamous NSCLC who have received 1 prior lines of therapy and 2 or more prior lines of therapy", 
                "measure": "Anti-tumor efficacy (dose expansion subjects)", 
                "safety_issue": "No", 
                "time_frame": "Until end of study"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693562"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "If data allow, noncompartmental PK parameters (AUC, Cmax, CL, t\u00bd) will be estimated.", 
                "measure": "Area under the concentration time curve, maximum concentration, clearance, half-life after administration of MEDI4736.", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "The immunogenic potential of MEDI4736 will be assessed by summarizing the number and percentage of subjects who develop detectable anti-drug antibodies (ADAs).", 
                "measure": "Number and percentage of subjects who develop detectable anti-drug antibodies (ADAs).", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months after the last dose of MEDI4736."
            }, 
            {
                "description": "The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR", 
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Until end of study"
            }, 
            {
                "description": "The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for\n\u2265 12 weeks)", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "Until end of study"
            }, 
            {
                "description": "Duration of response will be defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.", 
                "measure": "Duration of response (DR)", 
                "safety_issue": "No", 
                "time_frame": "Until end of study"
            }, 
            {
                "description": "Progression-free survival is the time interval from the start of treatment with MEDI4736 until the documentation of confirmed immune-related disease progression or death due to any cause, whichever occurs first.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Until end of study"
            }, 
            {
                "description": "Overall survival will be determined as the time from the start of treatment with MEDI4736 until death.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drug until death or up to 2 years"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}